Use of 1H MRS of Plasma and Tissue in Cancer Detection and Management

  • John K. Saunders
  • Ian C. P. Smith
Part of the Developments in Oncology book series (DION, volume 61)


In November 1986 Fosse! and coworkers published an article (1) which caused a flurry of activity in both NMR and oncology laboratories around the world. This article suggested that 1H NMR of plasma could be used to detect the presence of cancer. Although never stated as such, the inference was that this test could be used to screen an asymptomatic population for cancer. Since we were already applying 1H NMR in cancer detection and management we decided to test the waters with respect to application of the Fossel test.


Triglyceride Concentration Adrenocortical Carcinoma Borderline Ovarian Tumour Methyl Group Ratio Ottawa Civic Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fossel ET, Carr JM, McDonagh J: Detection of malignant tumours. New Eng. J. Med. 315:1369–1376, 1986.PubMedCrossRefGoogle Scholar
  2. 2.
    Chmurny GN, Hilton BD, Halverson D et al: An NMR blood test for cancer: A critical assessment. NMR in Biomedicine 1:136–150, 1988.PubMedCrossRefGoogle Scholar
  3. 3.
    Wilding P, Senior MB, Inubushi T, Ludwick ML: Assessment of proton nuclear magnetic resonance for detection of malignancy. Clin. Chem. 34:505–511, 1988.PubMedGoogle Scholar
  4. 4.
    Dowd TL, Kaplan BA, Gupta RK, Aisen P: Detection of malignant tumors: Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. Magn. Reson. Med. 5:395–397, 1987.PubMedCrossRefGoogle Scholar
  5. 5.
    Holmes KT, Mackinnon WB, May GL et al: Hyperlipidemia as a biochemical basis of magnetic resonance plasma test for cancer. NMR in Biomedicine 1:44–49, 1988.PubMedCrossRefGoogle Scholar
  6. 6.
    Smith ICP, Smart CR, Feller W et al: Magnetic resonance spectroscopy of plasma from populations of normal, high risk, and cancer patients: Correlation with plasma triglycerides. New Engl. J. Med. (in press).Google Scholar
  7. 7.
    Barclay M, Skipski VP: Lipoproteins in relation to cancer. Prog. Biochem. Pharmacol. 10:78, 1975.Google Scholar
  8. 8.
    Wieczorek AJ, Rhyner C, Block LH: Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans. Proc. Natl. Acad. Sci. USA 82:3455–3459, 1985.PubMedCrossRefGoogle Scholar
  9. 9.
    Mountford CE, May GL, Wright LC: Proteolipid identified by magnetic resonance spectroscopy in plasma of a patient with borderline ovarian tumour. Lancet 1:829–834, 1987.PubMedCrossRefGoogle Scholar
  10. 10.
    Morrisett JD, Guyton JR, Gaubatz JW, Gotto AM: Lipoprotein(a): Structure, metabolism and epidemiology. In: Plasma Lipoproteins, Vol. 4, A.M. Gotto (ed), Elsevier Science Publishers, B.V., pp. 129–152, 1987.CrossRefGoogle Scholar
  11. 11.
    Wright LC, Sullivan DR, Muller M et al: Elevated apolipoprotein(a) levels in cancer patients. Int. J. Cancer 43:241–244, 1989.PubMedCrossRefGoogle Scholar
  12. 12.
    Mountford CE, Wright LC, Holmes KT et al: High resolution proton NMR studies of metastatic cancer cells. Science 226:1415–1418, 1984b.CrossRefGoogle Scholar
  13. 13.
    Mountford CE, Saunders JK, May GL et al: Classification of human tumours by high resolution resonance spectroscopy. Lancet 8482:651–653, 1986a.CrossRefGoogle Scholar
  14. 14.
    Remin M, Somorjai RL, Deslauriers R et al: 1H magnetic resonance of human tumours. Analysis of the transverse relaxation of the methylene protons using continuous distributions of relaxation times. NMR in Biomedicine, in press.Google Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1990

Authors and Affiliations

  • John K. Saunders
  • Ian C. P. Smith

There are no affiliations available

Personalised recommendations